Terms: = Breast cancer AND TRIM27, DASS-46L4_6, RFP, 5987, ENSG00000234495, RNF76 AND Treatment
27169 results:
1. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
[TBL] [Abstract] [Full Text] [Related]
2. Targeted photodynamic therapy technique of Janus nanoparticles on breast cancer.
Montaseri H; Abrahamse H
Artif Cells Nanomed Biotechnol; 2024 Dec; 52(1):270-277. PubMed ID: 38696132
[TBL] [Abstract] [Full Text] [Related]
3. The effectiveness of personalised surveillance and aftercare in breast cancer follow-up: a systematic review.
van Maaren MC; van Hoeve JC; Korevaar JC; van Hezewijk M; Siemerink EJM; Zeillemaker AM; Klaassen-Dekker A; van Uden DJP; Volders JH; Drossaert CHC; Siesling S;
Support Care Cancer; 2024 May; 32(5):323. PubMed ID: 38695938
[TBL] [Abstract] [Full Text] [Related]
4. Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells.
Favaretto G; Rossi MN; Cuollo L; Laffranchi M; Cervelli M; Soriani A; Sozzani S; Santoni A; Antonangeli F
Cancer Immunol Immunother; 2024 May; 73(6):113. PubMed ID: 38693312
[TBL] [Abstract] [Full Text] [Related]
5. Surgical treatment of breast Lymphedema: A Distinct Pathology With Unique Challenges.
Szymanski K; Chun Fat S; Brazio PS
Ann Plast Surg; 2024 May; 92(5S Suppl 3):S315-S319. PubMed ID: 38689412
[TBL] [Abstract] [Full Text] [Related]
6. A Comparative Analysis of Implant-sparing Plan
Onal C; Bozca R; Dolek Y; Elmali A; Guler OC
In Vivo; 2024; 38(3):1412-1420. PubMed ID: 38688603
[TBL] [Abstract] [Full Text] [Related]
7. Neoadjuvant Chemotherapy in Patients with HER2-Negative breast cancer: A Report from Clinical breast cancer Registry of Iran.
Roudini K; Mirzania M; Yavari T; Seyyedsalehi MS; Nahvijou A; Zebardast J; Saadat M; Khajeh-Mehrizi A
Arch Iran Med; 2024 Apr; 27(4):206-215. PubMed ID: 38685847
[TBL] [Abstract] [Full Text] [Related]
8. breast density knowledge and willingness to delay treatment for pre-operative breast cancer imaging among women with a personal history of breast cancer.
Smith RE; Sprague BL; Henderson LM; Kerlikowske K; Miglioretti DL; Wernli KJ; Onega T; diFlorio-Alexander RM; Tosteson ANA
Breast Cancer Res; 2024 Apr; 26(1):73. PubMed ID: 38685119
[TBL] [Abstract] [Full Text] [Related]
9. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
10. Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment.
Bullen A; Ryan M; Ennis H; Gray E; Loría-Rebolledo LE; McIntyre M; Hall P
BMJ Open; 2024 Apr; 14(4):e076798. PubMed ID: 38684245
[TBL] [Abstract] [Full Text] [Related]
11. Design and Evaluation of NSAID Derivatives as AKR1C3 Inhibitors for breast cancer treatment through Computer-Aided Drug Design and In Vitro Analysis.
Fonseca-Benítez V; Acosta-Guzmán P; Sánchez JE; Alarcón Z; Jiménez RA; Guevara-Pulido J
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675620
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
13. Real-World treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic breast cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract] [Full Text] [Related]
14. The Efficacy of Fat Grafting on Treating Post-Mastectomy Pain with and without breast Reconstruction: A Systematic Review and Meta-Analysis.
Chen J; Alghamdi AA; Wong CY; Alnaim MF; Kuper G; Zhang J
Curr Oncol; 2024 Apr; 31(4):2057-2066. PubMed ID: 38668055
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic Factors Associated with Tumor Recurrence and Overall Survival in Soft Tissue Sarcomas of the Extremities in a Colombian Reference cancer Center.
Díaz Casas SE; Villacrés JM; Lehmann Mosquera C; García Mora M; Mariño Lozano I; Ángel Aristizábal J; Suarez Rodríguez R; Duarte Torres CA; Sánchez Pedraza R
Curr Oncol; 2024 Mar; 31(4):1725-1738. PubMed ID: 38668034
[No Abstract] [Full Text] [Related]
16. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract] [Full Text] [Related]
17. Comparing symptom clusters in cancer survivors by cancer diagnosis: A latent class profile analysis.
Lee LJ; Han CJ; Saligan L; Wallen GR
Support Care Cancer; 2024 Apr; 32(5):308. PubMed ID: 38662054
[TBL] [Abstract] [Full Text] [Related]
18. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
[TBL] [Abstract] [Full Text] [Related]
19. Implementation of a Mindful Walking Intervention in breast cancer Patients After Their Primary Oncologic treatment: Results of a Qualitative Study Within a Randomized Controlled Trial.
Ortiz M; Schröder ML; Brinkhaus B; Stöckigt B
Integr Cancer Ther; 2024; 23():15347354241237972. PubMed ID: 38654515
[TBL] [Abstract] [Full Text] [Related]
20. Exploring a repurposed candidate with dual hIDO1/hTDO2 inhibitory potential for anticancer efficacy identified through pharmacophore-based virtual screening and in vitro evaluation.
Aboomar NM; Essam O; Hassan A; Bassiouny AR; Arafa RK
Sci Rep; 2024 Apr; 14(1):9386. PubMed ID: 38653790
[TBL] [Abstract] [Full Text] [Related]
[Next]
